Efipladib

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530102

CAS#: 381683-94-9

Description: Efipladib, also known as PLA902, is a phospholipase inhibitor potentially for the treatment of osteoarthritis and rheumatoid arthritis. In studies, Efipladib was shown to decrease nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid.


Chemical Structure

img
Efipladib
CAS# 381683-94-9

Theoretical Analysis

MedKoo Cat#: 530102
Name: Efipladib
CAS#: 381683-94-9
Chemical Formula: C40H35Cl3N2O4S
Exact Mass: 744.14
Molecular Weight: 746.140
Elemental Analysis: C, 64.39; H, 4.73; Cl, 14.25; N, 3.75; O, 8.58; S, 4.30

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Efipladib; PLA-902; PLA 902; PLA902;

IUPAC/Chemical Name: 4-(3-(1-benzhydryl-5-chloro-2-(2-(((3,4-dichlorophenyl)methyl)sulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic

InChi Key: HIZOPJQOPKRKFM-UHFFFAOYSA-N

InChi Code: InChI=1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)

SMILES Code: O=C(O)C1=CC=C(CCCC2=C(CCNS(=O)(CC3=CC=C(Cl)C(Cl)=C3)=O)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=C2C=C(Cl)C=C6)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 746.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nickerson-Nutter CL, Goodwin D, Shen MW, Damphousse C, Duan W, Samad TA, McKew JC, Lee KL, Zaleska MM, Mollova N, Clark JD. The cPLA2α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. Neuropharmacology. 2011 Mar;60(4):633-41. doi: 10.1016/j.neuropharm.2010.11.025. PubMed PMID: 21146550.

2: McKew JC, Lee KL, Shen MW, Thakker P, Foley MA, Behnke ML, Hu B, Sum FW, Tam S, Hu Y, Chen L, Kirincich SJ, Michalak R, Thomason J, Ipek M, Wu K, Wooder L, Ramarao MK, Murphy EA, Goodwin DG, Albert L, Xu X, Donahue F, Ku MS, Keith J, Nickerson-Nutter CL, Abraham WM, Williams C, Hegen M, Clark JD. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl )-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem. 2008 Jun 26;51(12):3388-413. doi: 10.1021/jm701467e. PubMed PMID: 18498150.

3: Yao M, Xie C, Kiang MY, Teng Y, Harman D, Tiffen J, Wang Q, Sved P, Bao S, Witting P, Holst J, Dong Q. Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget. 2015 Oct 27;6(33):34458-74. doi: 10.18632/oncotarget.5277. PubMed PMID: 26416244; PubMed Central PMCID: PMC4741466.

4: Niknami M, Vignarajan S, Yao M, Hua S, Witting PK, Kita Y, Shimizu T, Sved P, Patel MI, Dong Q. Decrease in expression or activity of cytosolic phospholipase A2alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochim Biophys Acta. 2010 Jul;1801(7):731-7. doi: 10.1016/j.bbalip.2010.03.003. PubMed PMID: 20227521.

5: Zheng Z, He X, Xie C, Hua S, Li J, Wang T, Yao M, Vignarajan S, Teng Y, Hejazi L, Liu B, Dong Q. Targeting cytosolic phospholipase A2 α in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation. Oncotarget. 2014 Dec 15;5(23):12304-16. PubMed PMID: 25365190; PubMed Central PMCID: PMC4322978.

6: Burke JE, Babakhani A, Gorfe AA, Kokotos G, Li S, Woods VL Jr, McCammon JA, Dennis EA. Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. J Am Chem Soc. 2009 Jun 17;131(23):8083-91. doi: 10.1021/ja900098y. PubMed PMID: 19459633; PubMed Central PMCID: PMC2762749.

7: Hua S, Yao M, Vignarajan S, Witting P, Hejazi L, Gong Z, Teng Y, Niknami M, Assinder S, Richardson D, Dong Q. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochim Biophys Acta. 2013 Jun;1831(6):1146-57. doi: 10.1016/j.bbalip.2013.02.011. PubMed PMID: 23500889.